Weight loss jabs affecting Greggs, boss says

Greggs said demand shifts tied to popular GLP-1 weight-loss drugs are leading customers to choose smaller portions and higher-protein, higher-fibre options, weighing on its sales mix and contributing to lacklustre profits and a muted near-term forecast. Management has begun rolling out smaller-portion and protein-rich items (including a new egg-pot) to capture this segment; Tesco similarly cited fresh and high-protein sales growth. The trend, reinforced by analyst commentary and new UK junk‑food advertising restrictions, implies structural menu and product-mix changes for food retailers that could pressure traditional high-fat bakery lines and force margin and assortment adjustments.

Analysis

Market structure: GLP-1 driven appetite change disproportionately helps large grocers and fresh/protein suppliers (e.g., TSCO.L, MKS.L private label lines) while hurting high-calorie, on-the-go bakery/snack incumbents (GRG.L, casual-dining). Expect margin mix-shift: grocers can up-sell higher-margin protein SKUs and capture share from independents; pastry volumes likely to fall 3-7% over 6–18 months under moderate adoption scenarios, pressuring same-store sales for niche bakers.

Risk assessment: Near-term (days–weeks) risk is headline-driven earnings revisions and ad/regulatory shifts (UK junk-food ad ban impacts discovery). Short-term (3–9 months) depends on GLP-1 prescription growth — if UK adult penetration >3–5% within 12 months, revenue disruption becomes structural; long-term (1–3 years) supply-chain realignment (higher pea/soy protein demand, lower commodity wheat demand) is plausible. Tail risks include sudden policy curbs on GLP-1 access (reversal) or pharma shortages that reverse consumption trends.

Trade implications: Implement directional and relative-value trades: long scaled exposure to large grocers and protein/meal-prep brands; short selective high-calorie food retailers. Use options to limit capital: buy 3–9 month puts on weak QSR/bakery names or call spreads on supermarkets to define risk. Rebalance after quarterly grocery volumes and next 60-day prescription/adoption datapoints.

Contrarian angles: The market may over-penalize legacy bakers without valuing their ability to re-price or pivot SKUs (smaller portions can be sold at higher per-calorie price). Historical parallels (health-driven beverage shifts) show incumbents often retain margin via premiumization. Therefore shorts on strong-balance-sheet retailers that rapidly adapt may be crowded and risky; focus shorts where brand/scale can’t pivot quickly.

Key Decisions for Investors

• Establish a 1.5–2.5% portfolio long position in TSCO.L (Tesco) over 6–12 months: thesis = scalable fresh/protein mix capture; set a 12-month target +15–25% and a stop-loss at -8%. Increase to 4% if Tesco reports fresh-food sales growth >200 bps vs total grocery in any quarter.
• Initiate a 1–2% short position in GRG.L (Greggs) or buy 6-month puts 8–12% OTM sized to 1–2% risk: target -20–30% over 3–9 months driven by volume erosion; cover if Greggs discloses protein/portion SKUs >10% of revenue or issues upward guidance.
• Execute a pair trade: long TSCO.L (2%) vs short GRG.L (1%) to express structural share shift while limiting market beta; rebalance after next UK grocery volumes release or if GLP-1 prescription penetration exceeds 3% of adults within 6 months.
• Use options as defined-risk plays: buy 3–6 month put spreads on casual-dining/independent bakery stocks with implied vol < historical realized vol to cap cost; buy 6–12 month call spreads on supermarket tickers to capture secular premiumization of fresh/protein, roll depending on quarterly sales trends.